(Q35580992)

9 August 2017

1 reference

title

Bicalutamide monotherapy for early stage prostate cancer: an update (English)

1 reference

9 August 2017

Bicalutamide Monotherapy for Early Stage Prostate Cancer: An Update (English)

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096491.61731.38

31 March 2024

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096491.61731.38

31 March 2024

author name string

Peter Iversen

1

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

full work available at URL

9 August 2017

http://api.elsevier.com/content/article/PII:S0022534701682569?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096491.61731.38

http://api.elsevier.com/content/article/PII:S0022534701682569?httpAccept=text/plain

31 March 2024

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096491.61731.38

http://www.jurology.com/doi/pdf/10.1097/01.ju.0000096491.61731.38

31 March 2024

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096491.61731.38

31 March 2024

1 reference

9 August 2017

170

1 reference

9 August 2017

6 Pt 2

1 reference

9 August 2017

S48-52; discussion S52-4

1 reference

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate

9 August 2017

1

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096491.61731.38

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

31 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096491.61731.38

Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study

31 March 2024

4

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096491.61731.38

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

31 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096491.61731.38

Treatment options for early prostate cancer

31 March 2024

7

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096491.61731.38

Progressive osteoporosis during androgen deprivation therapy for prostate cancer

31 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096491.61731.38

BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP

31 March 2024

9

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096491.61731.38

Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function

31 March 2024

10

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096491.61731.38

The bicalutamide Early Prostate Cancer Program. Demography

31 March 2024

11

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096491.61731.38

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

31 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096491.61731.38

A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No.

31 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000096491.61731.38

31 March 2024

Identifiers

1 reference

9 August 2017

1 reference